Abstract

The plant-associated bacterium Pseudomonas syringae pv. syringae simultaneously produces two classes of metabolites: the small cyclic lipodepsinonapeptides such as the syringomycins and the larger cyclic lipodepsipeptide syringopeptins SP22 or SP25. The syringomycins inhibit a broad spectrum of fungi (but particularly yeasts) by lipid-dependent membrane interaction. The syringopeptins are phytotoxic and inhibitory to Gram-positive bacteria. In this study, the fungicidal activities of two major syringopeptins, SP22A and SP25A, and their mechanisms of action were investigated and compared to those of syringomycin E. SP22A and SP25A were observed to inhibit the fungal yeasts Saccharomyces cerevisiae and Candida albicans although less effectively than syringomycin E. S. cerevisiae mutants defective in ergosterol and sphingolipid biosyntheses were less susceptible to SP22A and SP25A but the relative inhibitory capabilities of SRE vs. SP22A and SP25A were maintained. Similar differences were observed for capabilities to cause cellular K+ and Ca2+ fluxes in S. cerevisiae. Interestingly, in phospholipid bilayers the syringopeptins are found to induce larger macroscopic ionic conductances than syringomycin E but form single channels with similar properties. These findings suggest that the syringopeptins target the yeast plasma membrane, and, like syringomycin E, employ a lipid-dependent channel-forming mechanism of action. The differing degrees of growth inhibition by these lipodepsipeptides may be explained by differences in their hydrophobicities. The more hydrophobic SP22A and SP25A might interact more strongly with the yeast cell wall that would create a selective barrier for their incorporation into the plasma membrane.

Highlights

  • In addition to well-characterized small cyclic lipodepsinonapeptides, Pseudomonas syringae pv. syringae produces larger cyclic lipodepsipeptides known as the syringopeptins

  • GROWTH INHIBITORY ACTIVITIES AGAINST YEASTS syringomycin E (SRE) and syringopeptins SP22A and SP25A inhibited the growth of different strains of S. cerevisiae and C. albicans ATCC 10231 (Table 1)

  • SP22A was ∼2-fold more active than SP25A and both were less inhibitory than SRE

Read more

Summary

Introduction

In addition to well-characterized small cyclic lipodepsinonapeptides, Pseudomonas syringae pv. syringae produces larger cyclic lipodepsipeptides known as the syringopeptins. Syringae produces larger cyclic lipodepsipeptides known as the syringopeptins. These compounds are composed of 22 or 25 amino acids (SP22 and SP25, respectively) with an octadepsipeptide ring structure and a 3-hydroxy fatty acyl chain. Isoforms of SP22 and SP25 possessing fatty acyl chains composed of 10 and 12 carbons are designated A and B homologs, respectively. They or close structural variants are produced by other P. syringae pathovars (Vassilev et al, 1996; Grgurina et al, 2005). Little is known about the antifungal properties of the syringopeptins inhibitory activities against yeasts including the pathogen Candida albicans are briefly mentioned in reports (Iacobellis et al, 1992; Lavermicocca et al, 1997; Grgurina et al, 2005)

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call